Mergers & Acquisitions Mergers & Acquisitions

Comment: Pfizer likely will face bumpier antitrust road for Seagen buy than it did for previous deals

By Flavia Fortes and Ilana Kowarski
  • 16 Mar 2023 19:10
  • 16 Mar 2023 19:10
Pfizer will likely face more antitrust questions over its $43 billion bid for cancer biotech company Seagen from the US Federal Trade Commission than it did over its other most recent acquisitions.

In 2022, Pfizer closed four transactions that didn’t face an in-depth look from the regulator. Pfizer saw the antitrust waiting period

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers

Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments


Latest News